Should I buy or sell Vyant Bio stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vyant Bio in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" VYNT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in VYNT, but not buy additional shares or sell existing shares. View VYNT analyst ratings or view top-rated stocks .

How have VYNT shares performed in 2023?

Vyant Bio's stock was trading at $0.7025 at the start of the year. Since then, VYNT stock has decreased by 74.7% and is now trading at $0.1775. View the best growth stocks for 2023 here .

How were Vyant Bio's earnings last quarter?

Vyant Bio, Inc. (OTCMKTS:VYNT) released its quarterly earnings data on Thursday, November, 11th. The company reported ($0.75) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.75). The company earned $1.51 million during the quarter, compared to the consensus estimate of $2.19 million. Vyant Bio had a negative net margin of 3,474.81% and a negative trailing twelve-month return on equity of 151.82%. During the same period last year, the company earned ($2.90) EPS.

When did Vyant Bio's stock split?

Shares of Vyant Bio reverse split on Wednesday, November 2nd 2022. The 1-5 reverse split was announced on Wednesday, November 2nd 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, November 2nd 2022. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

How do I buy shares of Vyant Bio?

Shares of VYNT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Vyant Bio Stock Price, News & Analysis (OTCMKTS:VYNT)

$0.18

0.00 (0.00%)

(As of 12/7/2023 ET)

Compare

Today's Range: $0.17
▼
$0.19
50-Day Range: $0.15
▼
$0.20
52-Week Range: $0.14
▼
$1.58

Volume: 1,816 shs
Average Volume: 168,915 shs
Market Capitalization: $1.12 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Analyst Forecasts Chart Financials Headlines Insider Trades Ownership SEC Filings Short Interest

About Vyant Bio Stock (OTCMKTS:VYNT)

Vyant Bio, Inc., a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson's disease (PD). The company is based in Cherry Hill, New Jersey.

VYNT Stock Price History

30 days | 90 days | 365 days | Advanced Chart

VYNT Stock News Headlines

November 11, 2023 | finanznachrichten.de

Vyant Bio, Inc.: Vyant Bio Provides Update on Winddown Activities

November 10, 2023 | msn.com

Vyant Bio expects to start liquidation payments in Q4 2024

December 8, 2023 | Edge On The Street (Ad)

An Unusual Way to Invest in Gold

Most financial experts recommend including gold in your investment mix to protect against rising prices and keep wealth secure. Investors are discovering a little-known way to benefit from gold, which offers the chance to gain from higher gold prices and mining successes while avoiding the costs of operating mines.

November 10, 2023 | finance.yahoo.com

Vyant Bio Provides Update on Winddown Activities

November 1, 2023 | finanznachrichten.de

Vyant Bio, Inc.: Vyant Bio Announces Stockholder Approval of Plan of Dissolution

November 1, 2023 | msn.com

Vyant Bio shareholders approve plan to dissolve company

November 1, 2023 | finance.yahoo.com

Vyant Bio Announces Stockholder Approval of Plan of Dissolution

October 26, 2023 | finance.yahoo.com

Lab Notes: Philadelphia health care investment firm closes two funds valued at over $500M

December 8, 2023 | Edge On The Street (Ad)

An Unusual Way to Invest in Gold

October 25, 2023 | finanznachrichten.de

Vyant Bio, Inc.: Vyant Bio Announces Completion of StemoniX Asset Sale

October 24, 2023 | finance.yahoo.com

Vyant Bio Announces Completion of StemoniX Asset Sale

October 19, 2023 | finance.yahoo.com

Vyant Bio Announces Stockholder Approval of Proposed Asset Sale; 64,110 Votes Needed to Approve Plan of Dissolution; and Adjournment of Special Meeting of Stockholders

October 11, 2023 | finance.yahoo.com

Vyant Bio Announces 77,522 Votes Needed to Approve Sale of Assets 175,721 Votes Needed to Approve Winddown of Business Adjournment of Special Meeting of Stockholders

September 30, 2023 | finanznachrichten.de

Vyant Bio, Inc.: Vyant Bio Announces Adjournment of Special Meeting of Stockholders

September 20, 2023 | finance.yahoo.com

Vyant Bio Announces Adjournment of Special Meeting of Stockholders

August 21, 2023 | yahoo.com

Medicare patients took unnecessary genetic cancer tests in man’s $463M scheme, feds say

August 21, 2023 | washingtonpost.com

‘Asian glow’ from alcohol isn’t just a discomfort. It’s a severe warning.

August 18, 2023 | msn.com

Gene that vastly increases chance of breast cancer found by scientists

August 17, 2023 | msn.com

The dangerous gene that vastly increases your chance of breast cancer

August 9, 2023 | msn.com

AI Can Find Cancer’s Origin: Study

July 18, 2023 | benzinga.com

Genprex – FDA Grants Fast Track Approval For Promising New Cancer Gene Therapy

July 17, 2023 | bizjournals.com

Vyant Bio enters into deal to sells its microBrain assets for $2.25M

July 17, 2023 | finance.yahoo.com

AxoSim Enters Into a Definitive Agreement to Acquire Vyant Bio's StemoniX Assets

July 6, 2023 | msn.com

Gene editing helped crack a 100-year-old mystery about cancer

July 3, 2023 | msn.com

Certain genetic mutations linked to treatment-resistant breast cancer, new study discovers

July 3, 2023 | msn.com

Testing begins for Orkney cancer gene link

June 29, 2023 | usatoday.com

Are you truly at risk for prostate cancer? Adding genetics may give more accurate PSA tests

See More Headlines

Receive VYNT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vyant Bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/11/2021
Today: 12/07/2023
Next Earnings (Estimated): 12/07/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Industry: Medical laboratories
Sub-Industry: N/A
Sector: Medical
Current Symbol: OTCMKTS:VYNT
CUSIP: N/A
CIK: 1349929
Web: stemonix.com
Phone: (201) 479-1357
Fax: 201-528-9201
Employees: 4
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-22,690,000.00
Net Margins: -3,474.81%
Pretax Margin: -3,281.86%
Return on Equity: -151.82%
Return on Assets: -97.14%

Debt

Debt-to-Equity Ratio: 0.04
Current Ratio: 2.86
Quick Ratio: 2.86

Sales & Book Value

Annual Sales: $666,000.00
Price / Sales: 1.69
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.69 per share
Price / Book: 0.11

Miscellaneous

Outstanding Shares: 6,329,000
Free Float: 5,724,000
Market Cap: $1.12 million
Optionable: Not Optionable
Beta: 1.68

5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

Mr. Andrew D.C. LaFrence CPA (Age 60)
President, CEO & CFO
Comp: $407.4k
Mr. Yung-Ping Yeh M.B.A. (Age 47)
M.S., P.M.P., Co-Founder & Director
Comp: $22.5k

Key Competitors

View All Competitors

VYNT Stock Analysis - Frequently Asked Questions

Should I buy or sell Vyant Bio stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vyant Bio in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" VYNT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in VYNT, but not buy additional shares or sell existing shares.
View VYNT analyst ratings or view top-rated stocks.
How have VYNT shares performed in 2023?: Vyant Bio's stock was trading at $0.7025 at the start of the year. Since then, VYNT stock has decreased by 74.7% and is now trading at $0.1775.
View the best growth stocks for 2023 here.
How were Vyant Bio's earnings last quarter?: Vyant Bio, Inc. (OTCMKTS:VYNT) released its quarterly earnings data on Thursday, November, 11th. The company reported ($0.75) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.75). The company earned $1.51 million during the quarter, compared to the consensus estimate of $2.19 million. Vyant Bio had a negative net margin of 3,474.81% and a negative trailing twelve-month return on equity of 151.82%. During the same period last year, the company earned ($2.90) EPS.

When did Vyant Bio's stock split?: Shares of Vyant Bio reverse split on Wednesday, November 2nd 2022. The 1-5 reverse split was announced on Wednesday, November 2nd 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, November 2nd 2022. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.
How do I buy shares of Vyant Bio?: Shares of VYNT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (OTCMKTS:VYNT) was last updated on 12/8/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial